Clinical trials: Glucagon
Pre-diabetes, Older Adults
Liraglutide and a Calorie Restricted Diet Augments Weight Loss and Decreases Risk of Type 2 Diabetes and CVD.
The goal of this study is to evaluate the hypothesis that the addition of liraglutide, a long-acting glucagon-like peptide 1 (GLP-1) analogue, to a calorie-restricted diet will lead to greater weight loss than will a…
- Trial name
- NCT01784965
- Testing
- liraglutide
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Stanford University
Type 1 Diabetes
Safety of Overestimation of a Meal Insulin Bolus in the Context of Dual-hormone Closed-loop Operation
In previous studies, investigators have studied if a pre-meal insulin bolus based on estimated carbohydrate meal size would alleviate the burden of carbohydrate counting without a significant degradation in postprandial glucose…
- Trial name
- NCT02626936
- Testing
- Dual-hormone closed-loop, Insulin, Glucagon
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Institut de Recherches Cliniques de Montreal
Type 1 Diabetes
Closed-loop Control of Glucose Levels (Artificial Pancreas) for 24 Hours in Adults and Adolescents With Type 1 Diabetes
Closed-loop strategy is composed of three components: glucose sensor to read glucose levels, insulin pump to infuse insulin and a dosing mathematical algorithm to decide on the required insulin dosages based on the sensor's…
- Trial name
- NCT01754337
- Testing
- Closed-loop system
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Institut de Recherches Cliniques de Montreal
Type 2 Diabetes
Efficacy and Safety of Semaglutide Injection vs Ozempic® in Patients With Type 2 Diabetes
This is a 32-week randomized, open-label, parallel-controlled biosimilar comparison study comparing the efficacy, safety and immunogenicity of the investigational drug and the active comparator in patients with type 2 diabetes…
- Trial name
- NCT06739044
- Testing
- Ozempic®, HDG1901
- Where
- China
- Volunteers
- 494 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Diabetes Mellitus, Type 2, Pre-diabetic
Glucagon-like Peptide-1 Metabolism and Acute Neprilysin Inhibition
Type 2 diabetes is common, increases in prevalence with age, and patients with diabetes have an increased risk of cardiovascular disease.
- Conditions
- Diabetes Mellitus, Type 2, Pre-diabetic, Hypertension, Elevated Blood Pressure
- Trial name
- NCT03508739
- Testing
- Sacubitril/Valsartan 200mg (blinded), Valsartan 160mg (blinded)
- Where
- United States
- Sponsor
- University of Pennsylvania
Type 2 Diabetes
To Evaluate the Response to Glucagon During Hypoglycemia
The purpose of this study is to evaluate the response to Glucagon versus the spontaneous hormonal response to low blood sugar levels in T2DM Patients treated with AZD1656 and Metformin
- Trial name
- NCT00817271
- Testing
- AZD1656, Glucagon
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- AstraZeneca
Type 1 Diabetes, Blood Glucose, Low
The Effect of Rapid and Slow Glucose Fall on the Subsequent Glucose Production in People With Type 1 Diabetes
In the effort of better understanding the glucose control in people with type 1 diabetes, in-depth insight into the physiology of hepatic glucose production and its influencing factors is essential.
- Conditions
- Type 1 Diabetes, Blood Glucose, Low, Glucose Metabolism Disorders
- Trial name
- RaSlo-19 (NCT04098549)
- Testing
- Rapid lowering of plasma glucose, Slow lowering of plasma glucose
- Where
- Denmark
- Volunteers
- 10 people
- Sponsor
- Steno Diabetes Center Copenhagen
GLP - 1
Exploring the Influence of Glucagon-like Peptide -1 (GLP-1) Medications on Food Cravings, Food Selection, and Food Intake Following Exposure to Food Advertisements
The purpose of this randomized control trial is to compare how food cravings, food selection, and food consumption change in response to frequent food advertisements compared to non-food advertisements in adults taking GLP-1…
- Trial name
- NCT07505134
- Testing
- Food advertisements, Tech advertisements
- Volunteers
- 50 people
- Sponsor
- Penn State University
Type1 Diabetes Mellitus
Glucagon-like Peptide-1 in Type 1 Diabetes
The hypotheses to be tested in this application is: GLP-1 will acutely protect arterial endothelial function and reduce pro-atherothrombotic and pro-coagulant effects of repeated hypoglycemia in T1DM.
- Trial name
- NCT04355832
- Testing
- Glucagon-like peptide-1
- Where
- United States
- Sponsor
- University of Maryland, Baltimore
Type2 Diabetes
Effect of Neprilysin on Glucagon-Like Peptide-1 in Patients With Type 2 Diabetes
Glucagon-like peptide-1(GLP-1) is secreted during a meal and increases glucose induced insulin secretion. The enzyme dipeptidyl peptidase 4(DPP-4) cleaves intact GLP-1 within minutes and DPP-4 inhibitors are therefore used for…
- Trial name
- NEPT2D (NCT03893526)
- Testing
- Entresto, Sitagliptin, Valsartan
- Where
- Denmark
- Volunteers
- 12 people
- Sponsor
- University of Copenhagen
Diabetes Mellitus, Type 1
Glucose-dependent Insulinotropic Polypeptide as a Safeguard Against Hypoglycemia in Patients With Type 1 Diabetes
In the present project the investigators will evaluate whether glucagonotropic properties of the gut-derived incretin hormone glucose-dependent insulinotropic polypeptide (GIP) may be utilized as a safeguard against hypoglycemia…
- Trial name
- NCT03556098
- Testing
- glucose-dependent insulinotropic peptide, Glucose-Dependent Insulin-Releasing Hormone[3-30], Saline Solution
- Where
- Denmark
- Volunteers
- 12 people
- Sponsor
- Steno Diabetes Center Copenhagen
Normal Healthy Volunteer, Safety After Oral Intake
A Research Study to Evaluate BLX-7006 in Healthy Adults
This study will test an oral medicine called BLX-7006, which acts like the hormone Glucagon-like Peptide-1 (GLP-1) to help control blood sugar and body weight. Current GLP-1 medicines are given by injection.
- Trial name
- NCT07140055
- Testing
- BLX-7006
- Where
- Australia
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Biolexis Therapeutics
Mental Disorder, Metabolic Disturbance
Is Saxenda® a Viable Treatment of Obese Patients in Forensic Psychiatry?
An open-label, multi-centre, 26-weeks clinical feasibility study. The objective is to explore whether Saxenda could be a feasible choice in the treatment of overweight, obesity and weight-related medical problems, in patients…
- Conditions
- Mental Disorder, Metabolic Disturbance, Feasibility, Overweight and Obesity
- Trial name
- NCT04781998
- Testing
- liraglutide 3 mg (Saxenda®) once-daily
- Where
- Denmark
- Volunteers
- 24 people
- Sponsor
- Anders Fink-Jensen, MD, DMSci
Hypoglycemia
Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of G-Pen(TM) (Glucagon Injection) to Treat Severe Hypoglycemia
The purpose of this study is to demonstrate that G-Pen(TM) glucagon is comparable to Lilly Glucagon(TM) in terms of safety and efficacy, as a treatment for severe hypoglycemia, a complication of diabetes.
- Trial name
- NCT01972152
- Testing
- G-Pen(TM) 1 mg, Lilly Glucagon(TM) 1 mg, G-Pen(TM) 0.5 mg
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Xeris Pharmaceuticals
Congenital Hyperinsulinism
CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital Hyperinsulinism
This is a Phase 2, multi-center, randomized, placebo-controlled, double-blind trial with open-label follow-up designed to assess the efficacy of Xeris Glucagon delivered as a continuous subcutaneous infusion to prevent…
- Trial name
- NCT02937558
- Testing
- Glucagon
- Where
- 5 sites in United States
- Volunteers
- 5 people
- Sponsor
- Xeris Pharmaceuticals
Atrial Fibrillation (AF), Obesity & Overweight
Danish Trial of Weight Loss to Reduce Atrial Fibrillation Progression
Obesity is an important risk factor for the development and progression of atrial fibrillation. Sustainable weight loss likely reduces the burden of atrial fibrillation, which has yet to be proven in adequately sized randomised…
- Trial name
- DANWRAP (NCT07816744)
- Testing
- Structured weight loss program including behavioral support and optional meal re-placement or pharmacotherapy with Glucagon-like peptide-1 receptor agonists (GLP1-RA), Standard Care (in control arm)
- Where
- 2 sites in Denmark
- Volunteers
- 480 people
- Sponsor
- Axel Brandes
PreDiabetes, Type 2 Diabetes
Linagliptin Response to OGTT in Prediabetes and Type 2 Diabetes Mellitus
There are studies that suggest glycemic response to incretin-based therapies differs between Asians and Caucasians, whereby Asians have better response compared to Caucasians.
- Trial name
- NCT05290506
- Testing
- Dipeptidyl-Peptidase IV Inhibitors
- Where
- Malaysia
- Volunteers
- 50 people
- Sponsor
- National University of Malaysia
Type 1 Diabetes Mellitus
Real-time Adaptation to Changes in Insulin Sensitivity
The purpose of this research study is to test an automated blood glucose control system that includes a new component designed to adapt to stress.
- Trial name
- NCT01261052
- Testing
- The Fading Memory Proportional Derivative/Adaptive Proportional Derivative Algorithm, The Adaptive Proportional Derivative Algorithm
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Legacy Health System
Type 2 Diabetes, Obesity
Randomisation to Endobarrier Alone Versus With Incretin Analogue in SustainEd Diabesity (REVISE-Diabesity)
New effective non-surgical treatments are needed for patients whose obesity and type 2 diabetes (T2DM) do not respond to current medical therapies.
- Conditions
- Type 2 Diabetes, Obesity, Diabesity
- Trial name
- NCT02055014
- Testing
- Liraglutide, Duodenal-jejunal bypass liner - Endobarrier device
- Where
- 4 sites in United Kingdom
- Volunteers
- 72 people
- Sponsor
- Sandwell & West Birmingham Hospitals NHS Trust
Pancreatic Cancer
A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs
EXCEED is a non-interventional post-authorisation safety study aiming to assess the risk of developing pancreatic cancer among type 2 diabetes mellitus (T2DM) patients who initiated exenatide compared to those who initiated other…
- Trial name
- EXCEED (NCT05663515)
- Testing
- Exenatide, Non-GLP-1 RA based glucose lowering drugs
- Where
- 8 sites in Denmark, Finland and 5 more
- Volunteers
- 24,000 people
- Sponsor
- AstraZeneca